Net Income

Dr. Frank Smith joins XenoSTART to lead its preclinical unit, aiming to leverage its vast patient-derived model library to speed up oncology drug development.

After a pivotal trial failure, Alector will present its new strategy at a key health conference, focusing on its innovative brain-delivery platform.

The maker of Wegovy and Ozempic announces a massive price cut. We explore what this means for patients, competitors, and the future of drug pricing.

Facing delisting, Hong Kong-based PTL Limited enacts a massive 1-for-80 share consolidation. But can this financial maneuver fix deeper business issues?

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

As Ring Energy preps its Q4 results, investors eye debt reduction, cost control, and 2026 strategy amid a challenging Permian market.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

Cell and gene therapy manufacturer OXB posts a dramatic turnaround to profitability, with surging revenues and an ambitious forecast for the coming years.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

Apellis Pharmaceuticals reports its first profitable year on strong SYFOVRE and EMPAVELI sales, but faces pressure to maintain momentum amid competition.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.

Life Time posts record 2025 earnings and a 230% Q4 profit surge, announcing a $500M share buyback and an aggressive expansion of its 'athletic country clubs'.

New Phase 1b data for oral drug pociredir reveals a robust boost in fetal hemoglobin, as Fulcrum Therapeutics secures a financial runway into 2029.

Planet Fitness reports a 12.1% revenue surge and adds 1.1 million members, proving its model's resilience even as Wall Street weighs future growth.

The junior miner sheds non-core assets to double down on its high-grade Mexican silver project while upgrading to a top-tier U.S. market.

With a record $1.2B order backlog and a bullish 2026 forecast, the specialty vehicle maker also announces a major leadership shift to drive its next growth phase.

With key conferences ahead, Supernus Pharmaceuticals must prove its strategy can deliver growth in the competitive central nervous system drug landscape.

Creatd Inc. executes a 1:20 reverse stock split to chase a national exchange listing. Is it a strategic masterstroke or a sign of deeper struggles?